Selected drugs that received regulatory approval in 2011. Source: BCIQ: BioCentury Online Intelligence

Company

Product

Indication

2011 approval

Amgen Inc. (NASDAQ:AMGN)

Xgeva denosumab

Skeletal-related events in adults with bone metastases from solid tumors

EU

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)/Alkermes Inc. (NASDAQ:ALKS)

Bydureon exenatide once weekly using Alkermes' drug delivery technology

Type II diabetes

EU

AstraZeneca plc (LSE:AZN; NYSE:AZN)

Brilinta ticagrelor

Reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS)

U.S.

AstraZeneca plc (LSE:AZN; NYSE:AZN)

Caprelsa vandetanib

Unresectable, locally advanced or metastatic medullary thyroid cancer

U.S.

AstraZeneca plc (LSE:AZN; NYSE:AZN)/Bristol-Myers Squibb Co. (NYSE:BMY)

Komboglyze saxagliptin/metformin

Type II diabetes

EU

Bayer AG (Xetra:BAY)

Gadavist gadobutrol injection

Diagnostic MRI to detect and visualize areas with disrupted blood-brain barrier and/or abnormal CNS vascularity

U.S.

Bayer AG (Xetra:BAY)/Johnson & Johnson (NYSE:JNJ)

Xarelto rivaroxaban

Prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery and prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)

U.S.

Biofrontera AG (Xetra:B8F)

Ameluz (BF-200 ALA)

Actinic keratosis

EU

BioSpecifics Technologies Corp. (NASDAQ:BSTC)/Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)/Pfizer Inc. (NYSE:PFE)

Xiapex collagenase clostridium histolyticum

Dupuytren's contracture in adult patients with a palpable cord

EU

Boehringer Ingelheim GmbH/Eli Lilly and Co. (NYSE:LLY)

Tradjenta linagliptin (Trajenta - EU)

Type II diabetes

U.S./EU

Bristol-Myers Squibb Co. (NYSE:BMY)

Yervoy ipilimumab

Unresectable or metastatic melanoma

U.S./EU